• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ligand Pharmaceuticals Incorporated

    5/14/25 12:31:11 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    LIGAND PHARMACEUTICALS INCORPORATED

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    53220K504

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    53220K504


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,028,066.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,028,066.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,028,066.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LIGAND PHARMACEUTICALS INCORPORATED
    (b)Address of issuer's principal executive offices:

    3911 SORRENTO VALLEY BLVD, SUITE 110 SAN DIEGO, CA 92121
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    53220K504
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 985,808 shares
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    985808

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    985808

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $LGND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGND

    DatePrice TargetRatingAnalyst
    4/10/2025$143.00Buy
    Stifel
    10/3/2024$135.00Outperform
    Oppenheimer
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    9/22/2021$174.00 → $180.00Overweight
    Barclays
    7/30/2021$200.00 → $190.00Buy
    Roth Capital
    More analyst ratings

    $LGND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

      JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand's senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions. "Ringing the Nasdaq Opening Bell marks an exciting milestone in our company's history. Over the past few years, we have made significant progress in transforming Ligand into a profitable and infrastructure-light organization focused on acquiring and generating royalties from a diverse portfolio of b

      5/14/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Participate in May Investor Conferences

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available for one-on-one meetings.Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 28, 2025.

      5/1/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Ligand Pharma with a new price target

      Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00

      4/10/25 12:42:08 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Ligand Pharma with a new price target

      Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00

      10/3/24 7:34:05 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ligand Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00

      7/30/24 6:24:41 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:05:16 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:04:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sabba Stephen L exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 8% to 32,584 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      4/16/25 9:34:19 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      11/1/24 4:07:52 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

      SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/14/24 6:26:25 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/13/24 5:08:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ligand Pharmaceuticals Incorporated

      SCHEDULE 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      5/14/25 12:31:11 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated

      10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      5/9/25 4:04:28 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      5/8/25 7:06:37 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    •  4D Pharma Appointments Paul Maier to the Board as Non-Executive Director

      LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational, international and financial management experience in the pharmaceutical and biotechnology industry, Paul will be able to provide 4D pharma with invaluable insights as we continue to execute

      3/1/21 7:05:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:05:16 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:04:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      8/9/24 5:52:17 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care